



Supplemental Figure 1: PFS Kaplan Meier curves according to interim BM uptake in the 38 patients with focal BM FDG lesions (5 patients with persistence of FDG BM uptake (Positive uptake), 33 patients without any significant BM uptake at interim (Negative uptake)). Log rank test: $p = 0,007$.

Supplemental Table 1: Correlations between BM biopsy and PET/CT (among the 178 patients with BM biopsy)

BM biopsy	Negative	Positive	<i>P value</i>
Total	166	12	
fPET			
Positive	32 (19.3%)	6 (50.0%)	<i>0.022</i>
Negative	134 (80.7%)	6 (50.0%)	
dPET			
Positive	51 (30.7%)	1 (8.3%)	<i>0.185</i>
Negative	115 (69.3%)	11(91.7%)	
Stage according to			
CT/PET	60 (36.1%)	0 (0.0%)	
Stage II	52 (31.3%)	6 (50.0%)	<i>0.021</i>
Stage III	54 (32.5%)	6 (50.0%)	
Stage IV			

Supplemental Table 2: Clinical correlations according to BM uptake on PET/CT: fPET⁺ and dPET⁺ groups compared to the overall population.

	fPET			dPET		
	+ (n=38) (Pure fPET ⁺ and f/dPET ⁺)	- (n=142)	p	+ (n=53) (Pure dPET ⁺)	- (n=127)	p
Positive bone marrow biopsy (%)	6 (15.0)	6 (4.3)	0.022	1 (1.9) ²	11 (8.7)	0.185
Bulky (%)	13 (34.2)	64 (45.1)	0.309	32 (60.4)	45 (35.4)	0.004
B Symptoms (%)	34 (89.5)	89 (62.7)	0.003	38 (71.7)	85 (66.9)	0.652
Age median (IQR)	41.8 (30.9,49.8)	38.1 (30.1,48.3)	0.468	35.6 (28.4,40)	42.4 (33.1,53.7)	<0.001
Sex, M (%)	21 (55.3)	61 (43)	0.242	17 (32.1)	51 (98.1)	0.185
Stage IV (%)	--	--	--	11 (20.8)	50 (39.4)	0.026
Hb (g/dL) mean (SD)	11.5 (1.9)	12.5 (2.0)	0.013	11.7 (1.9)	12.5 (2.1)	0.024
WBC (cell/ μ L) median (IQR)	11855 (8475,17037.5)	10600 (8200,12700)	0.056	12310 (10982.5,16452.5)	9680 (7100,12000)	<0.001
Lymphocyte (cell/ μ L) median (IQR)	1437.8 (1096,1983.1)	1605 (1138.5,1932.1)	0.609	1575 (1160.4,1917.1)	1571 (1099,1948.7)	0.759
LDH elevated ¹ (%)	15 (42.9)	35 (28.5)	0.158	17 (34.7)	33 (30.3)	0.713
Albumin, (g/dL) median (IQR)	3.7 (3.3,4.1)	4.1 (3.6,4.4)	0.002	4 (3.5,4.2)	4 (3.5,4.4)	0.347
Positive Interim PET (%)	12 (34.3)	38 (27.3)	0.547	14 (26.4)	36 (29.8)	0.79
Progression or relapse (%)	12 (32.4)	26 (18.3)	0.1	9 (17)	29 (23)	0.483
Alive (%)	35 (92.1)	136 (95.8)	0.401	52 (98.1)	119 (93.7)	0.286
Splenic uptake > liver (%)	3 (7.9)	16 (11.6)	0.768	11 (20.8)	8 (6.3)	0.009

Hb: hemoglobin; WB: white blood cells; IQR: InterQuartile Range; ¹over the limits referred by the local laboratory; ²all of those 3 patients had both dPET⁺ and fPET⁺.

Supplemental Table 2: Clinical correlations according to BM uptake on PET/CT: fPET⁺ and dPET⁺ groups compared to the overall population.

	fPET			dPET		
	+ (n=38) (Pure fPET ⁺ and f/dPET ⁺)	- (n=142)	p	+ (n=53) (Pure dPET ⁺)	- (n=127)	p
Positive bone marrow biopsy (%)	6 (15.0)	6 (4.3)	0.022	1 (1.9) ²	11 (8.7)	0.185
Bulky (%)	13 (34.2)	64 (45.1)	0.309	32 (60.4)	45 (35.4)	0.004
B Symptoms (%)	34 (89.5)	89 (62.7)	0.003	38 (71.7)	85 (66.9)	0.652
Age median (IQR)	41.8 (30.9,49.8)	38.1 (30.1,48.3)	0.468	35.6 (28.4,40)	42.4 (33.1,53.7)	<0.001
Sex, M (%)	21 (55.3)	61 (43)	0.242	17 (32.1)	51 (98.1)	0.185
Stage IV (%)	--	--	--	11 (20.8)	50 (39.4)	0.026
Hb (g/dL) mean (SD)	11.5 (1.9)	12.5 (2.0)	0.013	11.7 (1.9)	12.5 (2.1)	0.024
WBC (cell/ μ L) median (IQR)	11855 (8475,17037.5)	10600 (8200,12700)	0.056	12310 (10982.5,16452.5)	9680 (7100,12000)	<0.001
Lymphocyte (cell/ μ L) median (IQR)	1437.8 (1096,1983.1)	1605 (1138.5,1932.1)	0.609	1575 (1160.4,1917.1)	1571 (1099,1948.7)	0.759
LDH elevated ¹ (%)	15 (42.9)	35 (28.5)	0.158	17 (34.7)	33 (30.3)	0.713
Albumin, (g/dL) median (IQR)	3.7 (3.3,4.1)	4.1 (3.6,4.4)	0.002	4 (3.5,4.2)	4 (3.5,4.4)	0.347
Positive Interim PET (%)	12 (34.3)	38 (27.3)	0.547	14 (26.4)	36 (29.8)	0.79
Progression or relapse (%)	12 (32.4)	26 (18.3)	0.1	9 (17)	29 (23)	0.483
Alive (%)	35 (92.1)	136 (95.8)	0.401	52 (98.1)	119 (93.7)	0.286
Splenic uptake > liver (%)	3 (7.9)	16 (11.6)	0.768	11 (20.8)	8 (6.3)	0.009

Hb: hemoglobin; WB: white blood cells; IQR: InterQuartile Range; ¹over the limits referred by the local laboratory; ²all of those 3 patients had both dPET⁺ and fPET⁺.